Fenofibrate
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Fenofibrate: From Dyslipidaemia to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Fenofibrate is a lipid-lowering drug, and the pack lists no approved indication text for it in South Africa. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolemia (HoFH). The evidence is weak: 1 clinical trial was retrieved, and it tests a different drug (alirocumab), plus 11 publications, mostly reviews and older small studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the SAHPRA data supplied (fenofibrate is generally used for dyslipidaemia) |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the pack. Fenofibrate is a PPARalpha agonist. It mainly lowers triglycerides by increasing lipoprotein lipase activity and reducing ApoC-III. It also lowers LDL-C modestly and raises HDL-C.
HoFH is caused by loss of LDL receptor function, and fenofibrate does not act on that pathway. The high TxGNN score most likely reflects a shared lipid-metabolism network neighbourhood, not a validated mechanism.
Small older studies in familial hypercholesterolemia report modest LDL and apoB reductions. One 1984 cohort of type II hyperlipoproteinemia included a single HoFH patient, who showed the greatest fall in cholesterol. This is anecdotal. At best, fenofibrate would be an adjunct for residual triglycerides or mixed dyslipidaemia, not a primary LDL-lowering therapy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Open-label alirocumab (a PCSK9 inhibitor) in children and adolescents aged 8-17 with HoFH. Fenofibrate is not studied, so this gives no direct evidence. It only shows HoFH is an active trial area. |
No SANCTR or PACTR records were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6593751 | 1984 | Cohort | Pharmacol Res Commun | 22 type II hyperlipoproteinemia patients on fenofibrate 300 mg/day: LDL-C fell 24% (31% in familial hypercholesterolemia). One HoFH patient had the greatest fall. |
| 37979722 | 2024 | Review | Indian Heart J | Non-statin drugs review. The most definite fenofibrate indication is fasting triglycerides >500 mg/dl, with a modest reduction in cardiovascular events. |
| 24946816 | 2014 | Review | Intern Med J | Liver transplantation for HoFH when standard drugs and LDL apheresis are insufficient. |
| 2042836 | 1991 | Review | Ann N Y Acad Sci | Drug and surgical treatment of dyslipidaemic children. Fenofibrate is among agents that reduced lipids in familial hypercholesterolemia. |
| 26432726 | 2015 | Review | Indian Heart J | LDL-C lowering with statins and PCSK9 inhibitors. Indirect relevance. |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE dyslipidaemia management guideline. General context. |
| 35499807 | 2022 | Review | Curr Atheroscler Rep | Dyslipidaemia management in pregnancy. Indirect relevance. |
| 24734312 | 2014 | Pharmacokinetic study | Pharmacotherapy | Lomitapide (approved for HoFH) pharmacokinetic interactions with lipid-lowering drugs, including fenofibrate. |
| 14620392 | 2003 | Review | Pharmacotherapy | Ezetimibe review. Indirect relevance. |
| 9129869 | 1997 | Review | Drugs | Atorvastatin review. Indirect relevance. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 52/7.5/0769 | Pravafen 40/160Mg | Capsule | Not stated in the data supplied |
Pravafen is a fixed-dose pravastatin 40 mg / fenofibrate 160 mg combination. Essential Medicines List status is not available in the pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The only retrieved trial for HoFH tests a different drug. The fenofibrate literature is small and old, and the mechanism does not address the LDL receptor defect. The evidence supports fenofibrate only as a possible adjunct for mixed dyslipidaemia, not as HoFH therapy.
Rank 2, hyperlipoproteinemia, has L1 evidence (multiple completed Phase 3 RCTs of fenofibrate). It is essentially an established use of the drug rather than a new indication.
To proceed, the following is needed:
- The SAHPRA Professional Information (PI): approved indication, warnings and contraindications
- Confirmed mechanism of action data
- Fenofibrate-specific HoFH data, ideally a controlled study
- Specialist lipid-clinic input on where fenofibrate could sit alongside PCSK9 inhibitors and lomitapide
- Safety review for paediatric use and for interaction with other HoFH therapies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.